- Home
- ANY vs CANF Comparison
ANY vs CANF Comparison
Compare ANY & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANY
- CANF
- Stock Information
- Founded
- ANY N/A
- CANF 1994
- Country
- ANY United States
- CANF Israel
- Employees
- ANY N/A
- CANF N/A
- Industry
- ANY Finance: Consumer Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ANY Finance
- CANF Health Care
- Exchange
- ANY Nasdaq
- CANF Nasdaq
- Market Cap
- ANY 15.7M
- CANF 13.5M
- IPO Year
- ANY N/A
- CANF N/A
- Fundamental
- Price
- ANY $0.58
- CANF $0.66
- Analyst Decision
- ANY Strong Buy
- CANF Strong Buy
- Analyst Count
- ANY 1
- CANF 2
- Target Price
- ANY $3.00
- CANF $14.00
- AVG Volume (30 Days)
- ANY 1.3M
- CANF 333.8K
- Earning Date
- ANY 08-19-2025
- CANF 08-29-2025
- Dividend Yield
- ANY N/A
- CANF N/A
- EPS Growth
- ANY N/A
- CANF N/A
- EPS
- ANY N/A
- CANF N/A
- Revenue
- ANY $10,831,000.00
- CANF $674,000.00
- Revenue This Year
- ANY N/A
- CANF $461.72
- Revenue Next Year
- ANY N/A
- CANF N/A
- P/E Ratio
- ANY N/A
- CANF N/A
- Revenue Growth
- ANY N/A
- CANF N/A
- 52 Week Low
- ANY $0.36
- CANF $0.63
- 52 Week High
- ANY $1.90
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- ANY 43.87
- CANF 20.75
- Support Level
- ANY $0.46
- CANF $0.68
- Resistance Level
- ANY $0.61
- CANF $1.05
- Average True Range (ATR)
- ANY 0.05
- CANF 0.05
- MACD
- ANY -0.00
- CANF -0.00
- Stochastic Oscillator
- ANY 34.96
- CANF 7.89
About ANY Sphere 3D Corp.
Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Bitcoin Mining and Service and Product. The Bitcoin Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).